The reduction of Keap1 protein levels in cancer cells is mostly due to the epigenetic alteration of Keap1 through the hypermethylation of the CpG islands in the Keap1 promoter region [178], which thereby releases Nrf2 from the inhibitory regulation of Keap1 [178]. Here, NFE2L2 is linked to cancer.